Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 10, 2015, Pages 2709-2715

  Lim, Yen Ying ^a   Maruff, Paul ^b,c   Schindler, Rachel ^d   Ott, Brian R ^a   Salloway, Stephen ^a   Yoo, Don C ^a   Noto, Richard B ^a   Santos, Cláudia Y ^e   Snyder, Peter J ^a,e,f  

^a BROWN UNIVERSITY   (United States)

^b Scientific Division   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PFIZER INC   (United States)

^e UNIVERSITY OF RHODE ISLAND   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

Author keywords

Acetylcholine; Biomarker; Cognition; Early diagnosis; Preclinical Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLORBETAPIR F 18; SCOPOLAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE BROMIDE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; EXECUTIVE FUNCTION; FAMILY HISTORY; FEMALE; GROTON MAZE LEARNING TEST; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WORKING MEMORY; CHOLINERGIC NERVE CELL; COGNITION; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SYNAPTIC TRANSMISSION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CHOLINERGIC ANTAGONISTS; CHOLINERGIC NEURONS; COGNITION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCOPOLAMINE HYDROBROMIDE; SYNAPTIC TRANSMISSION;

EID: 84940957388     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.07.009     Document Type: Article

References (34)

1. Beach T.G., Honer W.G., Hughes L.H. Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease?. Acta Neuropathol. 1997, 93:146-153.
2. Beach T.G., Kuo Y.M., Spiegel K., Emmerling M.R., Sue L.I., Kokjohn K., Roher A.E. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2000, 59:308-313.
3. Brown D., Chisholm J.A., Owens J., Pimlott S., Patterson J., Wyper D. Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:296-300.
4. Caselli R.J., Dueck A.C., Osborne D., Sabbagh M.N., Connor D.J., Ahern G.L., Baxter L.C., Rapcsak S.Z., Shi J., Woodruff B.K., Locke D.E., Snyder C.H., Alexander G.E., Rademakers R., Reiman E.M. Longitudinal modeling of age-related memory decline and the APOE ε4 effect. N. Engl. J. Med. 2009, 361:255-263.
5. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., Pontecorvo M.J., Hefti F., Carpenter A.P., Flitter M.L., Krautkramer M.J., Kung H.F., Coleman R.E., Doraiswamy P.M., Fleisher A.S., Sabbagh M.N., Sadowsky C.H., Reiman E.P., Zehntner S.P., Skovronsky D.M. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283. AV45-A07 Study Group.
6. Corkin S. Acetylcholine, aging and Alzheimer's disease: implications for treatment. Trends Neurosci. 1981, 4:287-290.
7. Darby D.G., Fredrickson J., Pietrzak R.H., Maruff P., Woodward M., Brodtmann A. Reliability and usability of an internet-based computerized cognitive testing battery in community-dwelling older people. Comput. Hum. Behav. 2014, 30:199-205.
8. Fredrickson A., Snyder P.J., Cromer J., Thomas E., Lewis M., Maruff P. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Hum. Psychopharmacol. 2008, 23:425-436.
9. Gerretsen P., Pollock B.G. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin. Drug Saf. 2011, 10:751-765.
10. Grothe M., Zaborszky L., Atienza M., Gil-Neciga E., Rodriguez-Romero R., Teipel S.J., Amunts K., Suarez-Gonzalez A., Cantero J.L. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cereb. Cortex 2010, 20:1685-1695.
11. Grothe M., Heinsen H., Teipel S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol. Aging 2013, 34:1210-1220.
12. Grothe M.J., Heinsen H., Amaro E.J., Grinberg L.T., Teipel S.J. Cognitive correlates of basal forebrain atrophy and associated cortical hypometabolism in mild cognitive impairment. Cereb. Cortex 2015, Initiative AsDN, Epub ahead of print.
13. Jack C.R., Holtzman D.M. Biomarker modeling of Alzheimer's disease. Neuron 2013, 80:1347-1358.
14. Jack C.R., Wiste H.J., Lesnick T.G., Weigand S.D., Knopman D.S., Vemuri P., Pankratz V.S., Senjem M.L., Gunter J.L., Mielke M.M., Lowe V.J., Boeve B.F., Petersen R.C. Brain β-amyloid load approaches a plateau. Neurology 2013, 80:1-7.
15. Kerbler G.M., Fripp J., Rowe C.C., Villemagne V.L., Salvado O., Rose S., Coulson E.J. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease. Neuroimage Clin. 2014, 7:105-113. Alzheimer's Disease Neuroimaging Initiative.
16. Lim Y.Y., Ellis K.A., Pietrzak R.H., Ames D., Darby D., Harrington K., Martins R.N., Masters C.L., Rowe C., Savage G., Szoeke C., Villemagne V.L., Maruff P. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012, 79:1645-1652. AIBL Research Group.
17. Lim Y.Y., Prang K.H., Cysique L., Pietrzak R.H., Snyder P.J., Maruff P. A method for cross-cultural adaptation of a verbal memory assessment. Behav. Res. Methods 2009, 41:1190-1200.
18. Lim Y.Y., Villemagne V.L., Laws S.M., Pietrzak R.H., Snyder P.J., Ames D., Ellis K.A., Harrington K., Rembach A., Martins R.N., Rowe C.C., Masters C.L., Maruff P. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease. Mol. Psychiatry 2014, Epub ahead of print.
19. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein e and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9:106-118.
20. Maruff P., Lim Y.Y., Darby D., Ellis K.A., Pietrzak R.H., Snyder P.J., Bush A.I., Szoeke C., Schembri A., Ames D., Masters C.L. Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Pharmacol. Toxicol. 2013, 1:1-11. AIBL Research Group.
21. Mormino E.C., Betensky R.A., Hedden T., Schultz A.P., Ward A., Huijbers W., Rentz D.M., Johnson K.A., Sperling R.A. Amyloid and APOE E4 interact to influence short-term decline in preclinical Alzheimer's disease. Neurology 2014, 82:1760-1767. Alzheimer's Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing, Harvard Aging Brain Study.
22. Nair D., Dayyat E.A., Zhang S.X., Wang Y., Gozal D. Intermittent hypoxia-induced cognitive deficits are mediated by NADPH oxidase activity in a murine model of sleep apnea. PLoS One 2011, 6:e19847.
23. Petersen R.C., Aisen P.S., Beckett L.A., Donohue M.C., Gamst A.C., Harvey D.J., Jack C.R., Jagust W.J., Shaw L.M., Toga A.W., Trojanowski J.Q., Weiner M.W. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010, 74:201-209.
24. Potter P.E., Rauschkolb P.K., Pandya Y., Sue L.I., Sabbagh M.N., Walker D.G., Beach T.G. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol. 2011, 122:49-60.
25. Rentz D.M., Amariglio R.E., Becker J.A., Frey M., Olson L.E., Frishe K., Carmasin J., Maye J.E., Johnson K.A., Sperling R.A. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia 2011, 49:2776-2783.
26. Roher A.E., Kuo Y.M., Potter P.E., Emmerling M.R., Durham R.A., Walker D.G., Sue L.I., Honer W.G., Beach T.G. Cortical cholinergic denervation elicits vascular A beta deposition. Ann. N. Y. Acad. Sci. 2000, 903:366-373.
27. Rosenberg P.B., Wong D.F., Edell S.L., Ross J.S., Joshi A.D., Brašić J.R., Zhou Y., Raymont V., Kumar A., Ravert H.T., Dannals R.F., Pontecorvo M.J., Skovronsky D.M., Lyketsos C.G. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. Am. J. Geriatr. Psychiatry 2013, 21:272-278.
28. Rowe C.C., Bourgeat P., Ellis K.A., Brown B., Lim Y.Y., Mulligan R., Jones G., Maruff P., Woodward M., Price R., Robins P., Tochon-Danguy H., O'Keefe G., Pike K.E., Yates P., Szoeke C., Salvado O., Macaulay S.L., O'Meara T., Head R., Cobiac L., Savage G., Martins R., Masters C.L., Ames D., Villemagne V.L. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann. Neurol. 2013, 74:905-913.
29. Saint-Aubert L., Barbeau E.J., Péran P., Nemmi F., Vervueren C., Mirabel H., Payoux P., Hitzel A., Bonneville F., Gramada R., Tafani M., Vincent C., Puel M., Dechaumont S., Chollet F., Pariente J. Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. Eur. J. Nucl. Med. Mol. Imaging 2013, 3:43.
30. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221:555-563.
31. Snyder P.J., Bednar M.M., Cromer J.R., Maruff P. Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement. 2005, 1:126-135.
32. Snyder P.J., Lim Y.Y., Schindler R., Ott B.R., Salloway S., Daiello L., Getter C., Gordon C.M., Maruff P. Microdosing of scopolamine as a "cognitive stress test": rationale and test of a very low dose in an at-risk cohort of older adults. Alzheimers Dement. 2014, 10:262-267.
33. Spencer R.J., Wendell C.R., Giggey P.P., Katzel L.I., Lefkowitz D.M., Siegel E.L., Waldstein S.R. Psychometric limitations of the Mini-Mental State Examination among nondemented older adults: an evaluation of neurocognitive and magnetic resonance imaging correlates. Exp. Aging Res. 2013, 39:382-397.
34. Stark S.M., Yassa M.A., Lacy J.W., Stark C.E. A task to assess behavioral pattern separation (BPS) in humans: data from healthy aging and mild cognitive impairment. Neuropsychologia 2013, 51:2442-2449.